Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 83 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 M{XHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfZO|c1KGR? NVnCVWlvUUN3ME21MlcxPSBizszNJC=> M1HUZVE5PTV7NkGz
KP6.3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRPVB2PCCm M1[wVGlEPTB;MUCuOFI5KM7:TTC= M1;NelE5PTV7NkGz
KP7.7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO0JIQ> MkjhTWM2OD13NzDuUUA> M1v1bFE5PTV7NkGz
KB2P3.4 M4jYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\BZm05PCCm MVvJR|UxRTF{NDDNJC=> NVq5[W4xOTh3NUm2NVM>
KB2P1.21 NFL1XJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf2VWE1KGR? M2DCRWlEPTB;OEmwO{BvVSB? MV2xPFU2QTZzMx?=
U373-MG NVnEcVdES3m2b4TvfIlkKEG|c3H5 NHjuRZYyKM7:TTC= NWjOcWRrOjRiaB?= NHjyWldKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MWixPFk2PDdzMh?=
T98G NY\O[VRFS3m2b4TvfIlkKEG|c3H5 M{jUVFEh|ryPIB?= M1LVR|I1KGh? M{DYdWlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NFv2cGsyQDl3NEexNi=>
U87-MG M1z0e2N6fG:2b4jpZ{BCe3OjeR?= NFXCdWQyKM7:TTC= MofTNlQhcA>? MXrJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M{P4OVE5QTV2N{Gy
UVW NIfJVoZEgXSxdH;4bYMhSXO|YYm= NYrjSYZzPTByIH7N MV:yOEBp MXzJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M1\XZlE5QTV2N{Gy
HeLa NGPNR|RHfW6ldHnvckBCe3OjeR?= NYjHPYRDPTByIH7N Mn3tOEBp NXzhb4ZWS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NFfuSJoyQDl3NEexNi=>
HeLa MlXXSpVv[3Srb36gRZN{[Xl? M3rBdVEh|ryPIB?= NHziUWczPCCq MWDFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? MWixPFk2PDdzMh?=
T98G MVfGeY5kfGmxbjDBd5NigQ>? NHjCUpUyKM7:TTC= MmrNNlQhcA>? MXjFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? MlHzNVg6PTR5MUK=
L3 MVvDfZRwfG:6aXOgRZN{[Xl? M3nNTVUh|ryPIB?= NI\sZYI6PiCq MVzEUXNQ MXnTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= M4HOOVIxOTJ2NEW5
Granta-519 Mmj2R5l1d3SxeHnjJGF{e2G7 Ml3XOUDPxE1i NGnrc5U6PiCq M3jFOWROW09? MX3TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M{DiVVIxOTJ2NEW5
BT MX7DfZRwfG:6aXOgRZN{[Xl? NWrrdIZPPSEQvF2g NWj5TplPQTZiaB?= M2TVTmROW09? M3G5bnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NEi0S5IzODF{NES1PS=>
UPN2 M4HFemN6fG:2b4jpZ{BCe3OjeR?= Ml7KOUDPxE1i NWCyWmd4QTZiaB?= Mni2SG1UVw>? M1i0UHNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NWPmSII2OjBzMkS0OVk>
HBL-2 MVjDfZRwfG:6aXOgRZN{[Xl? NV;KeVVnPSEQvF2g M33qUlk3KGh? MnfqSG1UVw>? MlLUV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MVyyNFEzPDR3OR?=
JVM-2 NF\nNGVEgXSxdH;4bYMhSXO|YYm= MojjOUDPxE1i M1Pyelk3KGh? MnTjSG1UVw>? NWDMRmZwW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MXSyNFEzPDR3OR?=
Z138 M1P0cWN6fG:2b4jpZ{BCe3OjeR?= MoXDOUDPxE1i MnHKPVYhcA>? M2fTPGROW09? NFG2O2VUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MWiyNFEzPDR3OR?=
RWPE MVTJcpZie2m4ZTDBd5NigQ>? NVnZem9NOjVizszN MnPyOFghcA>? NHLrZ2pFVVOR Mlz4V4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> M13ZcVIyPTd3OE[1
VCaP Ml\STY53[XOrdnWgRZN{[Xl? MoPGNlUh|ryP NXq0RlRKPDhiaB?= NGLWRohFVVOR MnrhV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NGnyT5czOTV5NUi2OS=>
Mouse H2AX−/− ES Cells MWTDfZRwfG:6aXOgRZN{[Xl? MoHyNk42KM7:TR?= NV7XfINkOjBiaB?= NVPNUYd{W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NHzWOG8zOzN3NUS4PS=>
Mouse ATM−/− ES Cells M3rKfWN6fG:2b4jpZ{BCe3OjeR?= MWeyMlUh|ryP MlzHNlAhcA>? NHPZeIZUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> M2XOdVI{OzV3NEi5
H1650 M{T1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf5[FMzOCEQvF2= M2GweVE1PCCq NIfZSm9KSzVyPUG1MlQ4KM7:TR?= NHH5PJczOzJ|OUiwPS=>
H1650PTEN+ NF3n[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLqNlAh|ryP M2rxfVE1PCCq MVHJR|UxRTVyLkizJO69VQ>? Mn\CNlMzOzl6MEm=
PC-9 M1TBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfpNlAh|ryP MXGxOFQhcA>? M2\FXWlEPTB;NT64PEDPxE1? NHPvfoEzOzJ|OUiwPS=>
PC-9PTEN− M4O4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiyNEDPxE1? MYSxOFQhcA>? NXPB[3FuUUN3ME22MlUzKM7:TR?= NWXxdmpCOjN{M{m4NFk>
MDA-MB-231 M376Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\hOUBl[Xl? NGnre21KSzVyPU[uPUDPxE1? MWSyN|c3ODR7Nh?=
MDA-MB-468 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD5OUBl[Xl? NHXIXmpKSzVyPUWuNEDPxE1? MVGyN|c3ODR7Nh?=
BT20 NVPSTYVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;iXHlFPSCmYYm= NXHpTpNGUUN3ME23Mlch|ryP MUiyN|c3ODR7Nh?=
HCC1143 NEnnZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HVZVUh\GG7 NEHOeo9KSzVyPUGxMlEh|ryP NXfwcYpXOjN5NkC0PVY>
HCC1937 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu4eGtOPSCmYYm= MlXFTWM2OD1zMj62JO69VQ>? M37CXFI{PzZyNEm2
Hs578t NHfkfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGwU3o2KGSjeR?= NFrSUphKSzVyPUWuOkDPxE1? MoXqNlM4PjB2OU[=
Hs578t(si) M17memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorPOUBl[Xl? NFuxOVBKSzVyPUeuOUDPxE1? M4DxSVI{PzZyNEm2
BT474 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\QTpc2KGSjeR?= MXLJR|UxRTF7Lkig{txO NXHHO4NCOjN5NkC0PVY>
JIMT1 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DnVVUh\GG7 Mn;qTWM2OD15Lkeg{txO MV:yN|c3ODR7Nh?=
SKBR3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrLVYxwPSCmYYm= MmDQTWM2OD1zMT6xJO69VQ>? NV3qPYwyOjN5NkC0PVY>
SUM159 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXCOUBl[Xl? NIDiT25KSzVyPUSuNkDPxE1? NFL6clYzOzd4MES5Oi=>
CAMA1 NXXScJBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzJbW82KGSjeR?= NH7tcWtKSzVyPUG1Mlgh|ryP NH\TdnUzOzd4MES5Oi=>
MCF7 NVroV3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK1JIRigQ>? NILzVm9KSzVyPUWuPEDPxE1? M2W4XFI{PzZyNEm2
T47D MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[1JIRigQ>? M3:2NGlEPTB;OT62JO69VQ>? NWjGNHR1OjN5NkC0PVY>
HCT116 M1uwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSxNFAh|ryP MWq0PEBp MnTUSG1UVw>? M3myS2lEPTB;Mj61JO69VSB? MX:yOFU4Pzl2MR?=
SW1116 NU\lOGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi3bVlJOTByIN88US=> NHnUZpc1QCCq NUP3O2d{TE2VTx?= NWe0eppLUUN3ME2xNFAh|ryP NYPSeIhjOjR3N{e5OFE>
HT29 NI\tZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH4T5MyODBizszN MUG0PEBp NIH1fXVFVVOR MX\JR|UxRTF2Lkeg{txO MYiyOFU4Pzl2MR?=
LoVo MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yXm5FOTByIN88US=> MWC0PEBp M3rwdGROW09? MX7JR|UxRTF|LkSg{txO MmH5NlQ2Pzd7NEG=
HCT-15 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof5NVAxKM7:TR?= M2fk[lQ5KGh? MmnDSG1UVw>? NHHs[JpKSzVyPUGwJO69VQ>? MnfuNlQ2Pzd7NEG=
SW48 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\uNVAxKM7:TR?= M1z3[|Q5KGh? MY\EUXNQ MnTqTWM2OD17LkWg{txO NH3COYczPDV5N{m0NS=>
C-1 NXjLO2VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zYdlExOCEQvF2= NETnNVE1QCCq M174c2ROW09? NVjSdIRTUUN3ME23MlYh|ryP M2TRb|I1PTd5OUSx
RKO MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3vW4gyODBizszN NIDpe3o1QCCq MWDEUXNQ M{\DRmlEPTB;NT65JO69VQ>? M3rSdlI1PTd5OUSx
HCT116 NXqwPYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyyXHRPOTByIN88US=> Ml[2OFghcA>? NVK2bmlNTE2VTx?= NHfZW5FRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NVrCUXZLOjR3N{e5OFE>
SW1116 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW0[IQyODBizszN NVzidmpiPDhiaB?= M3npdGROW09? M3X0[nBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MkHoNlQ2Pzd7NEG=
HT29 M1[5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvrSGgyODBizszN NUPIfW0xPDhiaB?= MkjISG1UVw>? M1vUT3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NVzMNlRnOjR3N{e5OFE>
LoVo M4Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjWPFcyODBizszN NWK1cnV5PDhiaB?= MU\EUXNQ NXn6dWt5WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MV6yOFU4Pzl2MR?=
SW48 NV31S4FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;vNVAxKM7:TR?= NF;TS4w1QCCq NXfmfG82TE2VTx?= NX[zcplmWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NV7TPXpxOjR3N{e5OFE>
C-1 NHXkSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ZUYgyODBizszN MkLDOFghcA>? NV[yTpZYTE2VTx?= M2fpfnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M1;JWFI1PTd5OUSx
RKO M4Lsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHpdoFSOTByIN88US=> MWW0PEBp MVHEUXNQ NVWze3o1WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= Mmr2NlQ2Pzd7NEG=
HCT116 Mn32SpVv[3Srb36gRZN{[Xl? MWSxNEBvVQ>? NUm0O2pjOTJiaB?= NEfK[HNFVVOR NX7oNnpSUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 MYqyOFU4Pzl2MR?=
HT29 M4XjW2Z2dmO2aX;uJGF{e2G7 M{DKNFExKG6P MYGxNkBp NF\DV5ZFVVOR MnX2TY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 NEHsSHYzPDV5N{m0NS=>
TE-6 MWXGeY5kfGmxbjDBd5NigQ>? M4Tl[FUh|ryPIB?= MoDjNVIhcA>? NW\3NHlITE2VTx?= NIDLRmNKdmS3Y3XzJGczN01iYYLy[ZN1 NGTGZ|EzPDJzOUG2OC=>
TE-6 NVLpTWpnTnWwY4Tpc44hSXO|YYm= NWrmW2tZPSEQvF2g NUnvTnk3OjRiaB?= M13FNGROW09? MoXwTY5kemWjc3XzJIlvKGSxdXLs[UB{fHKjbnSgZpJm[Wu|IDjEV2J{MQ>? MmfJNlQzOTlzNkS=
Hep3B MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3pW5E1OCEQvF2g M4r2PVczKGh? NEfMTVlFVVOR M1[zUXN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS M3:wPFI2ODd{N{Wy
Huh7 NG[0fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfkUY41OCEQvF2g MkXSO|IhcA>? M{Hud2ROW09? MlTvV5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> MlG2NlUxPzJ5NUK=
Hep3B M1ztR2Z2dmO2aX;uJGF{e2G7 NV\FZodkPDBizszNJC=> NX\5boluOjRiaB?= NFu5Z41FVVOR M4LQZmlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= NIXQc|gzPTB5Mke1Ni=>
Huh7 NYP0fJJpTnWwY4Tpc44hSXO|YYm= NGqwXFU1OCEQvF2g MVqyOEBp MXrEUXNQ M3TkdWlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= MYGyOVA4Ojd3Mh?=
Hep3B NWjERVB3TnWwY4Tpc44hSXO|YYm= MVq0NEDPxE1i Mn2xNlQhcA>? NGn6cGtFVVOR NED6SXVKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= M2qyb|I2ODd{N{Wy
Huh7 NWjrNpc5TnWwY4Tpc44hSXO|YYm= NE\NWZo1OCEQvF2g MnvMNlQhcA>? MV;EUXNQ M1P4U2lv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= NV3FbIw4OjVyN{K3OVI>
SGC-7901 NVe2[HQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj5RohiOzEEoN88US=> NU\tPFJNPDhiaB?= NVTLUJVPTE2VTx?= NVrWSVFJSmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NHfpRoUzPTd4N{C3Oi=>
COLO-800 NUHH[25ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\WTWM2OD1yLkS0NVY1KM7:TR?= M4nJXHNCVkeHUh?=
EoL-1- NUPGUog1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\1d21JUUN3ME2wMlU3PDR4IN88US=> NUK5NXA6W0GQR1XS
NCI-H209 NVrkUmhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTUTWM2OD1yLkmxOVU3KM7:TR?= MYTTRW5ITVJ?
ES1 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwMUG0NFgh|ryP NHOz[oNUSU6JRWK=
NKM-1 M1TXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HkZ2lEPTB;MT6yOVM1PyEQvF2= MX3TRW5ITVJ?
NTERA-S-cl-D1 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPGVodKSzVyPUGuN|M{PDFizszN M2DrVHNCVkeHUh?=
MHH-ES-1 NGjGc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwNkKwOlch|ryP NYflU4VkW0GQR1XS
ES8 NFP1WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwN{K0NVQh|ryP M{nWUHNCVkeHUh?=
NCI-H720 NGHMRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DvOmlEPTB;Mj6yNFY6QSEQvF2= MXHTRW5ITVJ?
EW-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PrdmlEPTB;Mj6yO|U{PCEQvF2= NVjUZ5ZSW0GQR1XS
D-566MG NYWyeVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHJNFg5UUN3ME2yMlQ1PTZ6IN88US=> Mom1V2FPT0WU
697 NH6yfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDqTWM2OD1{Lki0NVc{KM7:TR?= MXnTRW5ITVJ?
ES5 NHXHZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwOEixPFkh|ryP MnvpV2FPT0WU
COLO-684 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojFTWM2OD1|LkWxOlk3KM7:TR?= MlThV2FPT0WU
ML-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX34[pdWUUN3ME2zMlYxODV6IN88US=> MXPTRW5ITVJ?
MC-IXC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fWSWlEPTB;Mz62N|M6OyEQvF2= MUDTRW5ITVJ?
DB M3:wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rIdGlEPTB;Mz62OVQ1QCEQvF2= M{K2NXNCVkeHUh?=
HCC2218 M1KwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HXd2lEPTB;Mz63N|ExOyEQvF2= MWrTRW5ITVJ?
NCI-H510A MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT5ZWtKSzVyPUOuPFI4OjRizszN NX[0[3E6W0GQR1XS
NCI-H526 M{fBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTXTnl3UUN3ME2zMlg3QTV6IN88US=> M3P2OnNCVkeHUh?=
MV-4-11 NHrSd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvvUYhKSzVyPUSuNVM{OzRizszN M4[yenNCVkeHUh?=
PA-1 NFjl[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr4bHI6UUN3ME20MlI2OjlizszN NEjaWJlUSU6JRWK=
EW-22 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\zPGlEPTB;ND6zOVg3KM7:TR?= MUnTRW5ITVJ?
KASUMI-1 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfrU2hDUUN3ME20MlQxOTB7IN88US=> M3\BTXNCVkeHUh?=
LU-139 M{T5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Cw[2lEPTB;ND63OVgzQSEQvF2= NYrqUpYzW0GQR1XS
SBC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmwd5pKSzVyPUSuPFA6ODhizszN M2Oxe3NCVkeHUh?=
H4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTRwOEm0OFMh|ryP NFL4SoRUSU6JRWK=
EW-11 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwMEiwO|Ih|ryP MX\TRW5ITVJ?
NBsusSR NGCyZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DpN2lEPTB;NT6xNlA2PSEQvF2= NHrz[VlUSU6JRWK=
RPMI-8226 NWr1d5B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\vcnVKSzVyPUWuNVUzPDRizszN NXr0dox6W0GQR1XS
DEL NG\QV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v0O2lEPTB;NT6yNFAxPiEQvF2= M4LjeXNCVkeHUh?=
ES4 NGHXc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;uTWM2OD13LkWxN|g6KM7:TR?= MVHTRW5ITVJ?
GCT NIfQfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK4TWM2OD13LkW2PFU3KM7:TR?= NFjyXVdUSU6JRWK=
NCI-H1048 M2mwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLIbYNsUUN3ME21Mlk4Ojd|IN88US=> MWjTRW5ITVJ?
NCI-SNU-1 NG\yeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi0dVlKSzVyPU[uNFIzKM7:TR?= MUDTRW5ITVJ?
ES7 NYPmd4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0bGlEPTB;Nj6wN|U4PyEQvF2= NV3CSlNlW0GQR1XS
SW982 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTZwMEmxN|ch|ryP M3Ho[nNCVkeHUh?=
L-363 NV;EdFhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X2WWlEPTB;Nj6zN|k4PCEQvF2= NFn3d5pUSU6JRWK=
HT-1080 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zre2lEPTB;Nj60PVY5OyEQvF2= NFvKdY5USU6JRWK=
HAL-01 M1jTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTZwNUGwPUDPxE1? Ml3qV2FPT0WU
NB14 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rpemlEPTB;Nj62OFA{QSEQvF2= NIPndWxUSU6JRWK=
EW-13 NHvyPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XtS2lEPTB;Nj63O|QzPCEQvF2= M{PISHNCVkeHUh?=
NY M1vwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f6Z2lEPTB;Nj65OFYxPSEQvF2= NG\mSYZUSU6JRWK=
NCI-SNU-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HFeWlEPTB;Nz6xNFQ{OyEQvF2= M4\SeXNCVkeHUh?=
MS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPDS3JmUUN3ME23MlE4PDl2IN88US=> MUnTRW5ITVJ?
EW-16 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrBTWM2OD15LkOxPFYyKM7:TR?= NUTuZmVrW0GQR1XS
LU-65 NVS4PZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTdwNEi0NVch|ryP M4\ZfHNCVkeHUh?=
HGC-27 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTdwN{KxO|Mh|ryP MlzJV2FPT0WU
CTB-1 NHHpUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTdwN{[xO|Uh|ryP MUnTRW5ITVJ?
5637 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTdwOUK4OkDPxE1? M{WzUXNCVkeHUh?=
U251 NILxTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXpPHNkUUN3ME23Mlk1ODF4IN88US=> MlKzV2FPT0WU
HOS Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuxVIJKSzVyPUiuNlMxODdizszN NIDzUIxUSU6JRWK=
DOHH-2 NYO4VYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2roSWlEPTB;OD6yN|U5KM7:TR?= M2HldXNCVkeHUh?=
EW-1 NHvZS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvafGx7UUN3ME24MlMxODh6IN88US=> MoLVV2FPT0WU
BV-173 NEjaXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfYdoFTUUN3ME24MlU2PTRizszN Mn7FV2FPT0WU
8-MG-BA M2nxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPkc3RbUUN3ME24MlY5QTh6IN88US=> MUfTRW5ITVJ?
NB69 NXXIdHZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXrVnhKSzVyPUiuO|A6OjFizszN Mnr0V2FPT0WU
NCI-H69 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTlwOUC5OlEh|ryP M4L6RnNCVkeHUh?=
RS4-11 NVzpSGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxTmlEPTB;MUGuNlIxQCEQvF2= MoLKV2FPT0WU
ONS-76 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkK5OFch|ryP MX7TRW5ITVJ?
SF539 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn0[HdKSzVyPUGxMlQ5QDlizszN NEDyTXVUSU6JRWK=
HuO-3N1 NH7TZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrKfXZKSzVyPUGxMlU4QTZizszN MVPTRW5ITVJ?
NCI-H1651 NV;pe3czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF{LkOxNVUh|ryP M3PDZ3NCVkeHUh?=
KARPAS-45 M1fqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF{LkO3OkDPxE1? NIDMVVNUSU6JRWK=
SK-NEP-1 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTSTWM2OD1zMj60OlA6KM7:TR?= NFHzeZJUSU6JRWK=
LAMA-84 M37TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\aW2pKSzVyPUGzMlExQTVizszN NWXPUIRQW0GQR1XS
NCI-H1155 NH7UWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDiWlBKSzVyPUGzMlI5PTZizszN NVHTXWRIW0GQR1XS
CTV-1 NULqTFlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGwToNbUUN3ME2xN{41PDVizszN MUHTRW5ITVJ?
QIMR-WIL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jDWGlEPTB;MUOuO|gyPCEQvF2= Mmj4V2FPT0WU
H9 NEfwZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPqXHNEUUN3ME2xN{45PDd3IN88US=> Ml3JV2FPT0WU
SK-MEL-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX1cJEzUUN3ME2xN{46OzR5IN88US=> MUnTRW5ITVJ?
HD-MY-Z NH:wS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF2LkC2N|ch|ryP Mn73V2FPT0WU
TI-73 NEDwb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfMXpRDUUN3ME2xOE4zOzV4IN88US=> M1PpNXNCVkeHUh?=
JVM-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jsfGlEPTB;MUWuOVcyPiEQvF2= NX3FOFBLW0GQR1XS
D-247MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe0ToVKSzVyPUG1MlU6OyEQvF2= NGn0VHFUSU6JRWK=
VA-ES-BJ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHQT5NmUUN3ME2xOU43ODl5IN88US=> M2jnTnNCVkeHUh?=
NOS-1 NFXudHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF3Lk[1NlIh|ryP MVLTRW5ITVJ?
MOLT-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nxOGlEPTB;MU[uO|UzKM7:TR?= MoXwV2FPT0WU
Mo-T NVT4NG9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\jSGlEPTB;MUeuNFg1QSEQvF2= MmTzV2FPT0WU
NCI-H1770 NVq2TGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXBTWM2OD1zNz6xOVQ{KM7:TR?= NXfYOGp3W0GQR1XS
COLO-320-HSR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP4TWM2OD1zNz6xPFI4KM7:TR?= NWWzdoJsW0GQR1XS
TE-12 M2n0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkTWM2OD1zNz63NFU1KM7:TR?= NFXm[HBUSU6JRWK=
NCI-H82 M{WwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHviOnhKSzVyPUG3Mlg4OjhizszN Mk\tV2FPT0WU
NEC8 NXjDNm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS5NVh3UUN3ME2xPE4yOzF4IN88US=> MmDrV2FPT0WU
HSC-3 NW\LS4ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF6Lke0NVQh|ryP NHLnSZpUSU6JRWK=
NCI-H1092 NGDac4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PNR2lEPTB;MUiuO|U6PSEQvF2= NGXRSHBUSU6JRWK=
NCI-H292 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXTNo04UUN3ME2xPU4xPDh7IN88US=> Mn3OV2FPT0WU
L-428 NWrtfGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXjOGN7UUN3ME2xPU42PTlizszN NX3vRZc{W0GQR1XS
LU-134-A NHn3cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF7LkW3NkDPxE1? MUHTRW5ITVJ?
GI-ME-N NFv2NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonKTWM2OD1zOT61O|Q4KM7:TR?= NH;xSmdUSU6JRWK=
ALL-PO NXnUZXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTrPHNUUUN3ME2xPU42QTd{IN88US=> MX3TRW5ITVJ?
D-283MED MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfqb5hKSzVyPUG5MlkyPSEQvF2= NV3VXGVmW0GQR1XS
D-423MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK3TWM2OD1zOT65PVY4KM7:TR?= MXfTRW5ITVJ?
CAKI-1 NYW5TXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vVWWlEPTB;MkCuNlIyQSEQvF2= MUfTRW5ITVJ?
ETK-1 NYfnTGZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33COGlEPTB;MkCuNlYyPSEQvF2= M1jBNnNCVkeHUh?=
G-402 M{O0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJyLkWzN|Qh|ryP MYXTRW5ITVJ?
HL-60 M3rBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTKXlhKSzVyPUKxMlE3OTNizszN NWH2b2pZW0GQR1XS
A2058 NYLXVG12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnflTWM2OD1{MT60OFc4KM7:TR?= NEnWfnFUSU6JRWK=
CHP-212 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJzLkmwOVEh|ryP NFPvO2NUSU6JRWK=
KY821 NYfoUplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrwTWM2OD1{MT65O|Uh|ryP MXPTRW5ITVJ?
TYK-nu NXGzdXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn30TWM2OD1{Mj6wOlUyKM7:TR?= MluzV2FPT0WU
JVM-2 NWTXTYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnzTWM2OD1{Mj6yPVg{KM7:TR?= NV[x[YNPW0GQR1XS
KU812 NH\mfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;XWmlEPTB;MkKuO|MyOiEQvF2= MXzTRW5ITVJ?
MKN28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XQOWlEPTB;MkKuPVAyPSEQvF2= MkHEV2FPT0WU
ECC10 NH;uN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHqTWM2OD1{Mz63OFEh|ryP NU\ifWxTW0GQR1XS
BHT-101 NFHNU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrG[3ZKSzVyPUK0MlAxODhizszN MlvGV2FPT0WU
DU-4475 M4TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonXTWM2OD1{ND6zN|M4KM7:TR?= MV;TRW5ITVJ?
769-P NX7id2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfwVoZPUUN3ME2yOE45PDZ4IN88US=> Ml:4V2FPT0WU
HEC-1 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDaUJRKSzVyPUK1MlQ1PSEQvF2= M33hZXNCVkeHUh?=
MOLT-13 NILQc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK4[JNKSzVyPUK1MlU{OzFizszN NYizZZJZW0GQR1XS
8505C M1fNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K4e2lEPTB;Mk[uOFk4PyEQvF2= MWLTRW5ITVJ?
GB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O5OWlEPTB;Mk[uO|E4PiEQvF2= MnnHV2FPT0WU
SF126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\3PXZkUUN3ME2yOk44PjR6IN88US=> M{e5dHNCVkeHUh?=
A4-Fuk Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTsfno6UUN3ME2yO{4yOjdzIN88US=> MmHmV2FPT0WU
OVCAR-8 NXrX[o5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzvTlVKSzVyPUK3MlE2OzlizszN NFf3V4RUSU6JRWK=
NCI-H1304 NFrqfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X2V2lEPTB;MkeuOVQh|ryP M3vG[3NCVkeHUh?=
GR-ST NV[2dY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr6OI9KUUN3ME2yPE4xPDdizszN MnX0V2FPT0WU
G-401 NX7GUWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6xSpQzUUN3ME2yPE42ODl4IN88US=> M3PPenNCVkeHUh?=
LXF-289 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnhOIR5UUN3ME2yPE42PjVzIN88US=> MmDtV2FPT0WU
DBTRG-05MG MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ6LkmyNFQh|ryP M1r4VXNCVkeHUh?=
YKG-1 M{HrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fMUWlEPTB;MkmuPFY5KM7:TR?= MoLWV2FPT0WU
GAMG NFXvSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvkTmEyUUN3ME2yPU46QTNizszN NHX0Zm9USU6JRWK=
HCT-116 M3rOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TxSWlEPTB;M{CuNFU1QCEQvF2= MmqyV2FPT0WU
S-117 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPDeXdKSzVyPUOxMlIzPTdizszN MXfTRW5ITVJ?
NCI-H1693 NH;yfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMRmlEPTB;M{OuOlU1OiEQvF2= Mnn4V2FPT0WU
A427 NEjQbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXVTWM2OD1|Mz65PVc3KM7:TR?= NWPLWoFRW0GQR1XS
HT-29 NHTjT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN2Lk[wN|Ih|ryP MX7TRW5ITVJ?
P12-ICHIKAWA M4[wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHEU|NKSzVyPUO0Mlc1QTFizszN M3rWTXNCVkeHUh?=
CAL-51 NGnaSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPqcI86UUN3ME2zOU4xPzB7IN88US=> NWnMWYR4W0GQR1XS
Ramos-2G6-4C10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjpdlJiUUN3ME2zOU4zPDJ3IN88US=> Ml[wV2FPT0WU
SCH MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN4LkSxO|Qh|ryP MWHTRW5ITVJ?
SK-MEL-24 M1T2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULzOVcxUUN3ME2zOk46ODR2IN88US=> M{\6cHNCVkeHUh?=
SW1573 M13ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz6TWM2OD1|OD63NlE3KM7:TR?= M2\WXnNCVkeHUh?=
BALL-1 NHrnc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe2T3ZKSzVyPUO5MlIyOjlizszN Mn7HV2FPT0WU
BE-13 M1;0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH3PFZEUUN3ME2zPU4{OjlizszN M2rLWXNCVkeHUh?=
GI-1 M1jSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDY[Xo6UUN3ME2zPU45PjR5IN88US=> M1GxOnNCVkeHUh?=
GOTO MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rPNWlEPTB;M{muPVE{QSEQvF2= MVvTRW5ITVJ?
A673 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XzN2lEPTB;NEGuNFM1OyEQvF2= NXTUbG17W0GQR1XS
KG-1 M3rSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfoT2FmUUN3ME20N{4{QTRizszN MXXTRW5ITVJ?
GP5d M1LFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR2LkC2OlYh|ryP MkPCV2FPT0WU
MFM-223 NUfhcI44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTR2LkGyNlgh|ryP MVnTRW5ITVJ?
OAW-42 NFPRSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC2OFdiUUN3ME20OE4zPjR|IN88US=> NUjNUocxW0GQR1XS
C8166 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{naemlEPTB;NEWuNFgzOiEQvF2= MljPV2FPT0WU
LU-99A M2PpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;kW4Q6UUN3ME20Ok4yOzJ{IN88US=> MXvTRW5ITVJ?
NCI-H23 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR4LkG3PFUh|ryP MnSwV2FPT0WU
HO-1-N-1 NF7yXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPUTWM2OD12Nz6wPVk5KM7:TR?= NYPZPYJkW0GQR1XS
A3-KAW MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD12Nz6xNFA4KM7:TR?= MkXOV2FPT0WU
CGTH-W-1 NHjGNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XEO2lEPTB;NEeuOVA3QSEQvF2= MlvpV2FPT0WU
DJM-1 NWfRXG1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLjepd2UUN3ME20O{42PDF|IN88US=> MYHTRW5ITVJ?
A101D MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7uS4tKSzVyPUS3MlY{PTdizszN MX;TRW5ITVJ?
BB30-HNC NGPlenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL1OYdDUUN3ME20PE4{ODd{IN88US=> NXXNWoVWW0GQR1XS
T98G NGLiR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR6LkS2N|Mh|ryP NEW3[3pUSU6JRWK=
NCI-H1573 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW3TWM2OD12OT60OFYzKM7:TR?= M4XLZXNCVkeHUh?=
MEG-01 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR7Lke0NVEh|ryP MoXXV2FPT0WU
WM-115 NIfUSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfrWIRKSzVyPUS5MlkzOjJizszN NUexRlJnW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System March 1 2019 Phase 1
NCT03740893 Not yet recruiting Breast Neoplasm Institute of Cancer Research United Kingdom|AstraZeneca February 2019 Phase 2
NCT03742895 Not yet recruiting Advanced Solid Neoplasms Merck Sharp & Dohme Corp. December 17 2018 Phase 2
NCT03740165 Not yet recruiting Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms Merck Sharp & Dohme Corp.|European Network for Gynaecological Oncological Trial Groups December 14 2018 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID